Anavex Life Sciences Corp. · NASDAQ:AVXL
Anavex Life Sciences — Investor Presentation (October 2019)
38 slides from Anavex Life Sciences's investor presentation, October 2019

Slide 1: Corporate Presentation
Corporate Presentation Christopher U Missling, PhD | President & CEO Nasdaq: AVXL | October 2019

Slide 2: Safe Harbor
SAFE HARBOR This presentation contains forward-looking statements made within the meaning of the Private Securities Litigation Reform Act of 1995 by Anavex® Life Sciences Corp. and its representatives. These statements can be identified by introductory words such as “expects,” “plans,” “intends,” “b

Slide 3: Anavex Life Sciences Portfolio Compounds
Anavex Life Sciences Portfolio Compounds CANDIDATE PRECLINICAL PHASE 1 PHASE 2 PHASE 3 ALZHEIMER’S DISEASE ANAVEX®2-73 PARKINSON’S DISEASE DEMENTIA *RETT SYNDROME *INFANTILE SPASMS FRAGILE X ANGELMAN’S *FRONT. DEMENTIA (FTD) ANAVEX®3-71 (AF710B) ALZHEIMER’S DISEASE PARKINSON’S DISEASE DEPRESSION ANA

Slide 4: New Therapeutic Strategy to Treat CNS Disorders
New Therapeutic Strategy to Treat CNS Disorders • Anavex utilizes genomic biomarkers in precision medicine to treat severe and devastating neurological disorders • Anavex is focusing on rare diseases with no available therapy (Rett syndrome) and high risk CNS patient populations (Alzheimer’s disease

Slide 5: Anavex at a Glance
Anavex at a Glance APPROACH Applying precision medicine to CNS disorders Patient selection based on genomic screening and biomarkers MECHANISM SIGMAR1 restoring cellular homeostasis FOCUS Finding effective treatments for neurodevelopmental and neurodegenerative diseases $ LARGE MARKETS Addressing un

Slide 6: Overview ANAVEX 2-73 Precision Medicine Clinical Trials
Overview ANAVEX®2-73 Precision Medicine Clinical Trials PHASE 2 PK and Safety & Efficacy (AVATAR) RETT SYNDROME** 7 21+33 ANAVEX®2-73-RS-001 STUDY (NCT03758924)* and ANAVEX®2-73-RS-002 AVATAR STUDY (NCT03941444)* Pediatric Safety & Efficacy (EXCELLENCE) RETT SYNDROME** 12 69 ANAVEX®2-73-RS-003 EXCEL

Slide 7: U.S. ANAVEX 2-73-RS-001 Trial (NCT03758924)
U.S. ANAVEX®2-73-RS-001 Trial (NCT03758924) • Phase 2, safety, tolerability, efficacy • Females > 18 years, classic RTT w/MECP2 mutation • Efficacy: • Primary*: Global severity (RSBQ, CGI-I) • Secondary: Behavior (ADAMS), Sleep (CSHQ), VAS (top caregiver concerns), Seizure diary • Response Biomarker

Slide 8: Efficacy: RSBQ & CGI-I Improved During Trial
Efficacy: RSBQ & CGI-I Improved During Trial RSBQ Total & CGI-I Correlated at Week 7 5 4 4 CGI-I Week 7 3 3 2 2 1 1 0 0 10 20 30 40 50 60 RSBQ Total Week 7 Spearman’s rho = 0.956, p = 0.003 8

Slide 9: Biomarkers: Plasma Glutamate & CSHQ (Sleep) Total Correlated at Week 7
Biomarkers: Plasma Glutamate & CSHQ (Sleep) Total Correlated at Week 7 40 CSHQ (Sleep) Total Week 7 35 30 25 20 15 10 10.00 15.00 20.00 25.00 30.00 35.00 40.00 Glutamate µmol/L Week 7 Spearman’s rho = 0.943, p = 0.005 9

Slide 10: Mechanism of Action
Mechanism of Action ANAVEX®2-73 Activation of Sigma-1 Receptor Effects on Neurons & Microglia: Glutamate as Efficacy Biomarker Glutaminase Glutaminase Glutamate Glutamate Glutamate 10

Slide 11: Conclusions on ANAVEX 2-73 in Rett Syndrome
Conclusions on ANAVEX®2-73 in Rett Syndrome • Despite the small sample size, Preliminary data demonstrates Encouraging Safety and Efficacy Signal on both Caregiver- & Clinician-based measures of Severity • Correlations with Key Biomarker related to disease Pathogenesis • High Level of Significance:

Slide 12: Catalysts to Drive Value
Catalysts to Drive Value The company is well positioned to achieve key clinical readouts Phase 2b/3 clinical trial in Alzheimer’s disease – ongoing Phase 2 clinical trial in Parkinson’s disease dementia (PDD) – ongoing Initiate Phase 2 clinical trial in Rett syndrome (RTT) Oral presentation at AAIC

Slide 13: SIGMAR1 Activation Modulates Multiple Aspects of Neurodegenerative Processes
SIGMAR1 Activation has been Shown to Modulate Multiple Aspects of Neurodegenerative Processes Sigma-1 receptor agonists ANAVEX®2-73 alleviates Tau Sigma-1 receptor agonists have been shown to restore pathology in neurodegenerative have a neuroprotective effect neuronal functions in disease models in

Slide 14: Autophagy as Key Protein Clearance Process
Autophagy as Key Protein Clearance Process: New Pharmacological Target in Neurodegeneration – achieved through SIGMAR1 Activation Sigma-1 receptor activation by ANAVEX2-73 enhances autophagy in C. elegans p ≤ 0.001 14

Slide 15: Genetic SIGMAR1 Variations Linked to Neurological Disorders
Genetic SIGMAR1 Variations Linked to Neurological Disorders The SIGMAR1 receptor is an integral • SIGMAR1 null mice display muscle membrane protein involved in cellular weakness, axonal degeneration homeostasis which targets restoration and motor neuron loss1 of neuroplasticity and cellular stress r

Slide 16: Quantitative PET Scan: Dose-dependent Target Engagement with Sigma-1 Receptor
Quantitative PET Scan: Dose-dependent ANAVEX®2-73 Target Engagement with the Sigma-1 Receptor 2D [18F]FTC-146-PET imaging of ANAVEX®2-73 0 mg /kg 1 mg/kg 10 mg/kg 30 mg/kg 100 Percent Sigma-1 Receptor 80 Sigma-1 receptor target occupancy Occupancy 60 study with 40 quantitative PET 20 scan of ANAVEX®

Slide 17: Patients Improvement Correlates with ANAVEX 2-73 and SIGMAR1 RNA Expression
Patients Improvement Correlates with ANAVEX®2-73 and SIGMAR1 RNA Expression Activities of Daily Living (ADCS-ADL)* Slope from Baseline to Week 57 p=0.015 ANAVEX®2-73 SIGMAR1 RNA expression (TPM) positive response in functional (ADCS- ADL) outcomes in Alzheimer’s disease patients corelate with SIGMAR

Slide 18: Significant Relationship between ANAVEX 2-73 Concentration and Patients Response
Significant Relationship between ANAVEX®2-73 Concentration and Patients Response Activities of Daily Living (ADCS-ADL)* ADCS-ADL (Delta from Baseline to Week 57) p=0.03 • High Concentration of ANAVEX®2-73 => High Delta ADCS-ADL (improved response) • # Plasma concentration of ANAVEX®2-73 is correlate

Slide 19: Higher Concentration Maintain ADCS-ADL Performance vs Lower Concentration
Patients Treated with Higher ANAVEX®2-73 Concentration Maintain ADCS-ADL* Performance vs Lower Concentration Cohort High Concentration cohort shows 88 % difference to low concentration cohort • High plasma concentration of ANAVEX®2-73 [>4.0 ng/ml] is correlated with the clinically administered dose

Slide 20: Higher Concentration Show Higher MMSE Performance
Patients Treated with Higher ANAVEX®2-73 Concentration Show Higher MMSE* Performance Compared to Lower Concentration High Concentration cohort shows 64 % less decline than low concentration cohort • High plasma concentration of ANAVEX®2-73 [>4.0 ng/ml] is correlated with the clinically (p < 0.0008)

Slide 21: Precision Medicine
Precision Medicine

Slide 22: Precision Medicine
Precision Medicine PHARMACOLOGY + GENOMIC = Patient Selection with Biomarker PHARMACOGENOMICS Increases Probability of Success 76% The ideal pharmacogenomics test will be able to determine: 55% • Potential for a medication to be 46% effective – for this person • The best dose of a medication – 28% f

Slide 23: Identification of Gene Signature from ANAVEX 2-73-Treated Patients
Identification of Gene “Signature” from ANAVEX®2-73-Treated Patients PRECISION MEDICINE • Genomic signature (WT SIGMAR1 gene) strongest responders to ANAVEX®2-73 • This genomic “biomarker” is drug specific, not indication specific, so it applies to all indications treated with ANAVEX®2-73 23

Slide 24: SIGMAR1 Gene Plays a Role in Protein Trafficking
SIGMAR1 Gene Plays a Role in Protein Trafficking Lumenal side Transmembrane region SIGMAR1 WT rs1800866 variant structure impairs protein trafficking Cytosolic side • Majority of the population (~80%) carries SIGMAR1 WT • Majority of patients (~80%) are expected to benefit from SIGMAR1 activation wi

Slide 25: SIGMAR1 WT Gene Associated with Improved Response
SIGMAR1 WT Gene Associated with Improved Response … … and validated at 148 weeks Delta MMSE Delta ADCS-ADL (Week 57 from Baseline) (Week 57 from Baseline) p=0.023 p=0.048 SIGMAR1 SIGMAR1 WT SIGMAR1 SIGMAR1 WT Pro2 variant (n=15) Pro2 variant (n=15) (rs1800866) (rs1800866) (n=5) (n=5) Source: H Hampe

Slide 26: Clinical Studies
Clinical Studies: • Rett Syndrome (RTT) • Parkinson’s Disease Dementia (PDD) • Alzheimer’s Disease (AD)

Slide 27: Pipeline Addresses both Rare and Large Indications
Pipeline Addresses both Rare and Large Indications Anavex pipeline and precision genetic medicine approach address unmet Alzheimer’s Disease (AD) needs of neurodevelopmental and neurodegenerative diseases ~5,700,000 patients1 Parkinson’s Disease (PD) ~1,000,000 patients2 Rett Syndrome (RTT) ~11,000

Slide 28: ANAVEX 2-73 Phase 2 Rett Syndrome Study N=21
ANAVEX®2-73 Phase 2 Rett Syndrome Study N=21 * 7 RTT pa<ent popula<on ANAVEX®2-73 Primary and Secondary Endpoints Active dose# • PK, Safety and tolerability of ANAVEX®2-73 • Diagnosis of • Behavioral symptoms confirmed RTT • Sleep function • Patients age >18 • Seizure activity Randomiza1on • DNA and

Slide 29: ANAVEX 2-73 Phase 2 Rett Syndrome AVATAR Study N=33
ANAVEX®2-73 Phase 2 Rett Syndrome AVATAR Study N=33 * 7 RTT pa<ent popula<on ANAVEX®2-73 Primary and Secondary Endpoints Active dose# • Safety and tolerability of ANAVEX®2-73 • Diagnosis of • Behavioral symptoms confirmed RTT • Sleep function • Patients age >18 • Seizure activity Randomiza1on • DNA

Slide 30: ANAVEX 2-73-RS-003 Rett Syndrome EXCELLENCE Study N=69
ANAVEX®2-73-RS-003 Rett Syndrome EXCELLENCE Study N=69 12 RTT pa<ent popula<on ANAVEX®2-73 Primary and Secondary Endpoints Active dose# • Safety and tolerability of ANAVEX®2-73 • Diagnosis of • Behavioral symptoms confirmed RTT • Sleep function • Patients age 5-18 • Seizure activity Randomiza1on • D

Slide 31: ANAVEX 2-73 Phase 2 Parkinson's Disease Dementia Study N=120
ANAVEX®2-73 Phase 2 Parkinson’s Disease Dementia Study N=120 14 PDD pa<ent popula<on Primary Endpoints • CDR Continuity of Attention ANAVEX®2-73 • Safety and tolerability of • Diagnosis of High dose# ANAVEX®2-73 probable Parkinson’s disease dementia Key Secondary Endpoints • MDS-UPDRS (PDD) • Sleep

Slide 32: Primary Endpoint CDR Continuity of Attention of PDD Ph2 Study
Primary Endpoint ‘CDR Continuity of Attention’ of PDD ANAVEX®2-73 Ph2 Study: Confirmed Beneficial Effect in Previous Ph2a AD Study Identification (IDN) in Cogstate battery assessed in ANAVEX®2-73 Ph2a AD Study comparable to CDR Continuity of Attention (choice reaction time paradigm) CDR ba;ery Cogst

Slide 33: ANAVEX 2-73 Ph2 AD Study - Cogstate IDN Improves within Weeks
ANAVEX®2-73 Ph2 AD Study - Cogstate IDN Improves within Weeks Cogstate IDN from Baseline Average Delta Reaction time (ms) ANAVEX®2-73 Cogstate IDN Weeks from Baseline Bars: Standard Error 33

Slide 34: Cogstate IDN: ANAVEX 2-73 Ph2a AD Patients vs Standard of Care
Cogstate IDN: ANAVEX®2-73 Ph2a AD Patients Improve within Weeks vs Standard of Care AD Patients AIBL-ROCS-AD* cohort as standard of care comparator Average Delta Reaction time (ms) SoC (AIBL- ANAVEX® Baseline data: Cogstate IDN ROCS-AD) 2-73 Participants (n) 35 32 MMSE (mean) 21.2 21.0 (p<0.01) ANAV

Slide 35: ANAVEX 2-73 Phase 2b/3 Alzheimer's Disease Study N=450
ANAVEX®2-73 Phase 2b/3 Alzheimer's Disease Study N=450 48 Primary Endpoints Early AD pa<ent popula<on • ADAS-Cog ANAVEX®2-73 • ADCS-ADL High dose# • Confirmed amyloid • Safety and tolerability of pathophysiology ANAVEX®2-73 (CSF/amyloid PET) Key Secondary Endpoints • Patients aged 60 to • CDR-SB 85

Slide 36: Investment Highlights
Investment Highlights • Pursuing Large Markets By Applying Precision Medicine to Develop Treatments For Neurodegenerative and Neurodevelopmental Diseases With High Unmet Needs – Novel genomic biomarker-driven programs to treat small patient populations such as Rett syndrome* as well as major public

Slide 37: Anavex Life Sciences Expertise
Anavex Life Sciences Expertise Management Team Christopher U. Missling PhD - President & CEO Walter E Kaufmann, MD - Chief Medical Officer Stephan Toutain, MS, MBA – Chief Operating Officer Emmanuel O Fadiran, RPh, PhD - SVP of Regulatory Affairs Daniel Klamer, PhD - VP of Business Development & Sci

Slide 38: Contact Us
Contact Us Corporate Office Anavex®Life Sciences Corp. 51 West 52nd Street, 7th floor New York, NY 10019 1-844-689-3939 Shareholder & Media Relations ir@anavex.com www.anavex.com NASDAQ: AVXL 38
Source: Internet Archive copy of anavex.com
More decks from Anavex Life Sciences Corp.
Proxy Contest (September 2026)25 slides · September 2026
AD/PD 2026, Copenhagen27 slides · Mar 21, 2026
Investor Presentation (February 2026)37 slides · February 2026
Investor Presentation (January 2026)37 slides · January 2026
Technical Presentation (February 2022)24 slides · Feb 2, 2022
Investor Presentation (September 2021)43 slides · Sep 13, 2021